Examining visual outcomes of bilateral trifocal IOL

Article

A new trifocal diffractive IOL (FineVision trifocal IOL, PhysIOL), implanted bilaterally, achieved a full range of adequate vision, satisfactory contrast sensitivity, and a lack of significant adverse photic phenomena, according to Spanish researchers reporting in BMC Ophthalmology.

A new trifocal diffractive IOL (FineVision trifocal IOL, PhysIOL), implanted bilaterally, achieved a full range of adequate vision, satisfactory contrast sensitivity, and a lack of significant adverse photic phenomena, according to Spanish researchers reporting in BMC Ophthalmology.

In a prospective, nonrandomized, observational study, 44 eyes of 22 patients were assessed before and three months after cataract surgery and IOL implantation. A Topcon KR-1 W wavefront analyser was used to determine aberrations, and LogMAR visual acuity was measured at distance, intermediate, and near. Contrast sensitivity was estimated using the Pelli-Robson letter chart and the CSV-1000 test. Both photopic and mesopic defocus curve testing was performed, and the Halo v1.0 program was used to assess adverse photic phenomena.

The findings:

• Mesopic pupil diameter mean aberration values were: total HOA RMS 0.41 ± 0.30 μm; coma 0.32 ± 0.22 μm; spherical aberration 0.21 ± 0.20 μm. 

• Binocular logMAR measurements were −0.05 ± 0.05 for corrected distance visual acuity, 0.15 ± 0.10 for distance corrected intermediate visual acuity, and 0.06 ± 0.10 for distance corrected near visual acuity.

• Mean Pelli-Robson contrast sensitivity was 1.40 ± 0.14 log units.

 

• CSV-1000 contrast sensitivity was 1.64 ± 0.14 log units at 3 cycles per degree (cpd), 1.77 ± 0.18 log units at 6 cpd, 1.44 ± 0.24 log units at cpd, and 0.98 ± 0.24 log units at 18 cpd.

• Significant differences were observed in the photopic and mesopic defocus curves.

• The mean disturbance index was 0.28 ± 0.22.

“Distance visual outcomes of the trifocal IOL FineVision were similar to those of monofocal IOLs, while near visual outcomes resembled those of bifocal diffractive IOLs,” the researchers wrote. “In addition, a real improvement in intermediate vision was noted, which was not associated with impairment of far or near vision. Trifocality did not lead to increased subjective visual discomfort in comparison to bifocality. Moreover, the indications and limitations of the FineVision lens do not differ from those of other diffractive lenses.”

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.